Observational Study of Thyroid, Parathyroid, and Adrenal Disease
This observational study aims to gather comprehensive information about thyroid, parathyroid, and adrenal diseases. Researchers will collect your medical information from your health records at MD Anderson and follow up with you for up to 15 years. The goal is to learn more about how these conditions affect people, including their diagnosis, treatment, and recovery. You can join if you are a patient at MD Anderson with a diagnosed or suspected endocrine disease. This study is collecting data to create a research database, which will help doctors better understand these conditions in the future. The current recruitment status is unclear.
- Study design
- This is an observational study planning to enroll 15,000 participants. It is not a drug trial but focuses on collecting data from medical records and follow-up.
- What's involved
- Your medical information will be collected from your records. You will also be contacted by phone or in clinic every 2-3 years for up to 15 years to check on your health.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for a length of 15 years, with contact every 2-3 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Nancy D. Perrier, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Research Database Compilation from Suspected or Diagnosed Endocrine Disease Participants by Medical Record Review and Follow Up15 years
Database compiled from continuous collection of data on patients diagnosed with surgical endocrine disease or patients who are at risk for developing endocrine neoplasia and/or disease, and by prospective follow-ups of patient populations.